It appears that Mind Cure Health (CSE: MCUR) is not quite yet done compiling its advisory team, this morning announcing yet another addition to its team of high profile advisors. Dr Wolfram Tetzlaff is the latest figure to join the team, an expert in neuroscience known for his work related to spinal cord injuries.
Presently, Tetzlaff serves as the director of ICORD, the International Collaboration on Repair Discoveries, at the University of British Colombia. His appointment to this role follows decades of research in his field, focused on neural protections and neural repair. Research in his lab is also said to include strategies to protect the spinal cord and brain in the early phases after injury and promoting recovery by stimulating endogenous stem cells.
The connection between spinal cord injuries and that of the work that Mind Cure focuses on, is that a number of comorbidities exist that are focuses of Mind Cure. Comorbidities such as depression are prevalent in spinal cord injury patients, as patients suddenly have to adjust to a new way of life in which they are not accustomed to.
“I look forward to joining the world-class team of scientists and researchers on the Mind Cure advisory board. Mental health is a universal concern in people with spinal cord injury, and unlike those who are terminally ill or may recover from an injury, these people have to adjust to a new normal, limited by their paralysis and other dysfunctions, for the rest of their life. Sadly, life span is shortened by many years – even decades – due to multiple causes, including an increased suicide rate. I believe there are more effective medicines and treatments in the pipeline, and I look forward to researching and discovering them with Mind Cure.”
Dr. Wolfram Tetzlaff
Mind Cure Health last traded at $0.76 on the CSE.
Sponsored · Cambria Gold Mines
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
